Anison Therapeutics
Anison Therapeutics Oy is a preclinical-stage biotech company based in Turku, Finland, focused on developing innovative topical therapeutics for HPV-related diseases. Their mission is to beat the papillomavirus with solutions that target the root cause of HPV infections, offering safe and effective treatments that go beyond symptom relief. The company aims to initiate preclinical phases by 2025 and has achieved milestones such as API production feasibility, prototype development, and proof-of-concept studies. They are committed to delivering targeted HPV solutions to improve patient quality of life.
Industries
Nr. of Employees
small (1-50)
Anison Therapeutics
Patents
Products
Topical cream for HPV-infected lesions
A topical cream formulation containing a novel active pharmaceutical ingredient intended to treat genital warts and premalignant HPV-associated infections by targeting viral oncoproteins and reducing lesion recurrence (preclinical stage).
Topical nasal spray for respiratory viral infections
A topical nasal spray formulation designed to block viral entry and propagation in nasal cavities using a combination of repurposed active pharmaceutical ingredients; described as a protective therapy for common enveloped respiratory viruses (preclinical/early development).
Topical cream for HPV-infected lesions
A topical cream formulation containing a novel active pharmaceutical ingredient intended to treat genital warts and premalignant HPV-associated infections by targeting viral oncoproteins and reducing lesion recurrence (preclinical stage).
Topical nasal spray for respiratory viral infections
A topical nasal spray formulation designed to block viral entry and propagation in nasal cavities using a combination of repurposed active pharmaceutical ingredients; described as a protective therapy for common enveloped respiratory viruses (preclinical/early development).
Services
End-to-end preclinical programs including prototype formulation, in vivo efficacy testing, and proof-of-concept studies to de-risk therapeutic candidates.
Partnerships with GMP-certified manufacturers and external service providers to produce APIs and support manufacturing development.
End-to-end preclinical programs including prototype formulation, in vivo efficacy testing, and proof-of-concept studies to de-risk therapeutic candidates.
Partnerships with GMP-certified manufacturers and external service providers to produce APIs and support manufacturing development.
Expertise Areas
- Preclinical development & in vivo efficacy testing
- Topical and mucosal (nasal) formulation development
- API synthesis and GMP manufacturing
- Targeted antiviral molecular therapeutics
Key Technologies
- Topical formulation
- Nasal spray formulation
- Targeted molecular degradation of viral proteins
- In vivo animal models for antiviral efficacy